Nicole F. Liachko

Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy.

Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity.

CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.

Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.

Loss of RAD-23 Protects Against Models of Motor Neuron Disease by Enhancing Mutant Protein Clearance.

The phosphatase calcineurin regulates pathological TDP-43 phosphorylation.

TDP-43/FUS in motor neuron disease: Complexity and challenges.

Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing.

Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.

Preventive action of benztropine on platinum-induced peripheral neuropathies and tumor growth.

Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects.

Tau tubulin kinases in proteinopathy.

Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort.

Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau.

Genome wide analysis reveals heparan sulfate epimerase modulates TDP-43 proteinopathy.

Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.

ARENA-based activity profiling of tau and TDP-43 transgenic .

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis.

Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice.

Regulation of TDP-43 phosphorylation in aging and disease.

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease.